查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球移植診斷市場：行業趨勢和預測 (-2029)
市場調查報告書
商品編碼
1156748

全球移植診斷市場：行業趨勢和預測 (-2029)

Global Transplant Diagnostics Market - Industry Trends and Forecast to 2029
出版日期: | 出版商: Data Bridge Market Research | 英文 699 Pages | 商品交期: 請詢問到貨日

價格

預計在 2022 年至 2029 年的預測期內，全球移植診斷市場規模的複合年增長率為 6.8%。

移植領域不斷進步的技術、全球移植手術數量的增加等是市場增長的主要驅動力。

本報告研究和分析了全球移植診斷市場，並提供了系統信息，包括市場概況、按細分市場和地區劃分的市場分析、競爭分析和公司概況。

內容

第一章介紹

第二章市場細分

第 3 章執行摘要

  • 流行病學
  • PESTEL 分析
  • 波特的五力分析
  • 創新

第 4 章全球移植診斷市場：監管

第 5 章關鍵戰略舉措

第 6 章行業洞察：

第 7 章市場概述

  • 司機
    • 移植手術數量增加
    • 移植領域的技術進步增加
    • 醫療費用增加
    • 移植前後採用交叉配型/嵌合體檢測
  • 約束因素
    • 器官移植費用高昂
    • 器官移植的風險和困難
  • 機會
    • 市場公司的戰略舉措
    • 增加公共、私人和政府對器官移植的投資
    • 人們越來越意識到器官移植的重要性
  • 任務
    • 器官移植過程中面臨的倫理問題
    • 器官捐獻者短缺以及器官捐獻者與每年所需器官數量之間的差距

第 8 章全球移植診斷市場：產品類型

  • 概覽
  • 移植診斷儀
    • 自動移液器分液器
    • 自動化系統
    • NGS設備
    • 讀者分析器
    • 移植診斷試劑盒
    • 其他套件
  • 移植診斷軟件
    • DNA 軟件
    • NGS 軟件
    • 數據管理軟件
    • 其他軟件
  • 移植診斷試劑
    • 單克隆抗體
    • 細胞毒性控制
    • 人血清
    • 其他試劑

第 9 章全球移植診斷市場：按技術分類

  • 概覽
  • 基於 PCR 的分子檢測
    • 實時熒光定量PCR
    • 序列特異性引物 PCR
    • 序列特異性寡核甘酸 PCR
    • 限制性片段長度多態性 (RFLP)
    • 其他基於 PCR 的分子檢測
  • 基於序列的分子檢測
    • 桑格測序
    • 下一代測序
    • 其他基於序列的分子檢測

第 10 章全球移植診斷市場：按植入物類型

  • 概覽
  • 實體器官移植
    • 腎移植
    • 肝移植
    • 心臟移植
    • 肺移植
    • 胰腺移植
    • 其他器官移植
  • 幹細胞移植
    • 骨髓移植 (BMT)
    • 外周血幹細胞移植
    • 臍帶血移植
    • 其他幹細胞移植
  • 軟組織移植
    • 植皮
    • 軟骨移植
    • 腎上腺自體移植物
    • 其他軟組織移植
  • 骨髓移植
    • 自體骨髓移植
    • 同種異體骨髓移植
    • 臍帶血移植
  • 其他

第 11 章全球移植診斷市場：按應用

  • 概覽
  • 診斷用途
    • 移植診斷儀
    • 移植診斷軟件
    • 移植診斷試劑
  • 研究用途
    • 移植診斷儀
    • 移植診斷軟件
    • 移植診斷試劑

第 12 章全球移植診斷市場：按最終用戶分類

  • 概覽
  • 醫院和移植中心
  • 商業服務提供商
  • 研究機構和學術機構
  • 其他

第 13 章全球移植診斷市場：按分銷渠道

  • 概覽
  • 直接投標
  • 零售
  • 其他

第 14 章全球移植診斷市場：按地區

  • 概覽
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳大利亞
    • 新加坡
    • 泰國
    • 馬來西亞
    • 印度尼西亞
    • 菲律賓
    • 其他亞太地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 俄羅斯
    • 西班牙
    • 土耳其
    • 荷蘭
    • 瑞士
    • 比利時
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 中東和非洲
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 埃及
    • 以色列
    • 其他中東/非洲

第 15 章全球移植診斷市場：公司概況

  • 公司份額分析：世界
  • 公司份額分析：北美
  • 公司份額分析：歐洲
  • 公司份額分析：亞太地區

第 16 章 SWOT 分析

第十七章公司簡介

  • ABBOTT
  • THERMO FISHER SCIENTIFIC INC.
  • F. HOFFMANN LA ROCHE LTD
  • TAKARA BIO INC.
  • HOLOGIC, INC
  • ADAPTIVE BIOTECHNOLOGIES
  • ALTONA DIAGNOSTICS
  • ARQUER DIAGNOSTICS LTD
  • BAG DIAGNOSTICS GMBH
  • BIOFORTUNA LIMITED
  • BIOMERIEUX
  • BIO-RAD LABORATORIES, INC.
  • BIOTYPE GMBH
  • CAREDX INC.
  • CLONIT SRL
  • DIAGNOSTICA LONGWOOD SL
  • DIASORIN S.P.A.
  • ELITECHGROUP
  • EUROFINS VIRACOR
  • HORIBA LTD
  • ILLUMINA, INC.
  • IMMUCOR
  • LABORATORY CORPORATION OF AMERICA HOLDINGS.
  • LUMINEX CORPORATION.（A SUBSIDIARY OF DIASORIN）
  • NANOSTRING
  • PATHONOSTICS
  • PRESERVATION SOLUTIONS, INC.
  • QIAGEN
  • RANDOX LABORATORIES LTD.
  • STRYKER
  • TRANSMEDICS
  • TRANSONIC.
  • ZIMMER BIOMET

第18章問卷調查

第19章相關報導

Global transplant diagnostics market is projected to register a CAGR of 6.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2022 to 2029.

Market Segmentation:

Global Transplant Diagnostics Market, By Product Type (Transplant Diagnostic Instrument, Transplant Diagnostic Software, Transplant Diagnostic Reagent), Technology (PCR-Based Molecular Assays, Sequencing-Based Molecular Assays), Transplant Type (Solid Organ Transplantation, Stem Cell Transplantation, Soft Tissue Transplantation, Bone Marrow Transplantation, Other Transplants), Application (Diagnostic Applications, Research Applications), End User (Research Laboratories and Academic Institutes, Hospital and Transplant Centers, Commercial Service Providers, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (U.S., Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and the Rest of Europe, China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, Philippines, Indonesia, and the Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, and the Rest of the Middle East and Africa) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the global transplant diagnostics market are:

Increase in the technological advancements in the field of transplant

Rising number of transplant procedures globally

Market Players:

Some of the major players operating in the global transplant diagnostics market are:

Hologic, Inc.

Biofortuna Limited

Takara Bio Inc.

Abbott

Diagnostica Longwood SL

Adaptive Biotechnologies

NanoString

Arquer Diagnostics Ltd

altona Diagnostics GmbH

ELITechGroup

DiaSorin S.p.A.

Horiba Ltd

EUROFINS VIRACOR

CareDx Inc.

Laboratory Corporation of America Holdings.

Randox Laboratories Ltd.

Thermo Fisher Scientific Inc.

Preservation Solutions, Inc.

TransMedics

Transonic

Stryker

Bio-Rad Laboratories, Inc.

Zimmer Biomet

QIAGEN

F. Hoffmann-La Roche Ltd

BIOMERIEUX

Illumina, Inc.

Luminex Corporation (A subsidiary of DiaSorin Company)

IMMUCOR

CLONIT srl

PathoNostics

Biotype GmbH

BAG Diagnostics GmbH

TABLE OF CONTENTS

1 INTRODUCTION 75

  • 1.1 OBJECTIVES OF THE STUDY 75
  • 1.2 MARKET DEFINITION 75
  • 1.3 OVERVIEW OF THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET 75
  • 1.4 CURRENCY AND PRICING 78
  • 1.5 LIMITATIONS 78
  • 1.6 MARKETS COVERED 78

2 MARKET SEGMENTATION 84

  • 2.1 MARKETS COVERED 84
  • 2.2 GEOGRAPHICAL SCOPE 85
  • 2.3 YEARS CONSIDERED FOR THE STUDY 86
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 87
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 90
  • 2.6 MULTIVARIATE MODELLING 91
  • 2.7 MARKET APPLICATION COVERAGE GRID 92
  • 2.8 SOURCE LIFELINE CURVE 93
  • 2.9 DBMR MARKET POSITION GRID 94
  • 2.10 VENDOR SHARE ANALYSIS 95
  • 2.11 SECONDARY SOURCES 96
  • 2.12 ASSUMPTIONS 96

3 EXECUTIVE SUMMARY 97

  • 3.1 EPIDEMOLOGY 103
  • 3.2 PESTEL_ANALYSIS 118
  • 3.3 PORTER'S FIVE FORCE 119
  • 3.4 TECHNOLOGICAL INNOVATIONS 120

4 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: REGULATIONS 121

5 KEY STRATEGIC INITIATIVES 125

6 INDUSTRIAL INSIGHTS: 126

7 MARKET OVERVIEW 128

  • 7.1 DRIVERS 130
    • 7.1.1 RISING NUMBER OF TRANSPLANT PROCEDURES 130
    • 7.1.2 INCREASE IN THE TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF TRANSPLANTS 130
    • 7.1.3 RISING HEALTHCARE SPENDING 130
    • 7.1.4 ADOPTION OF CROSS-MATCHING AND CHIMERISM TESTING DURING PRE- AND POST-TRANSPLANTATION 131
  • 7.2 RESTRAINTS 131
    • 7.2.1 HIGH COST OF ORGAN TRANSPLANTATION 131
    • 7.2.2 THE RISKS AND DIFFICULTIES OF ORGAN TRANSPLANTATION 131
  • 7.3 OPPORTUNITIES 132
    • 7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 132
    • 7.3.2 RISE IN PUBLIC, PRIVATE, AND GOVERNMENT FUNDING FOR ORGAN TRANSPLANTATION 132
    • 7.3.3 SURGE IN AWARENESS ABOUT THE IMPORTANCE OF ORGAN TRANSPLANTATION 133
  • 7.4 CHALLENGES 134
    • 7.4.1 ETHICAL CHALLENGES FACED DURING ORGAN TRANSPLANTATION 134
    • 7.4.2 LACK OF ORGAN DONORS OR GAP BETWEEN ORGAN DONORS AND ORGANS NEEDED ANNUALLY 134

8 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE 136

  • 8.1 OVERVIEW 137
  • 8.2 TRANSPLANT DIAGNOSTIC INSTRUMENTS 140
    • 8.2.1 AUTOMATED PIPETTORS & DISPENSERS 140
    • 8.2.2 AUTOMATED SYSTEMS 140
      • 8.2.2.1 NUCLEIC ACID EXTRACTION SYSTEM 141
      • 8.2.2.2 PCR SETUP 141
      • 8.2.2.3 OTHERS 141
    • 8.2.3 NGS INSTRUMENTS 141
    • 8.2.4 READERS & ANALYZERS 141
    • 8.2.5 TRANSPLANT DIAGNOSTIC KITS 141
      • 8.2.5.1 ASPERGILLUS SPP KITS 142
      • 8.2.5.2 P. JIROVECII KITS 142
      • 8.2.5.3 CMV KITS 142
      • 8.2.5.4 EBV KITS 142
      • 8.2.5.5 BKV KITS 143
      • 8.2.5.6 VZV KITS 143
      • 8.2.5.7 HSV1 KITS 143
      • 8.2.5.8 HSV2 KITS 143
      • 8.2.5.9 PARVOVIRUS B19 KITS 143
      • 8.2.5.10 ADENOVIRUS KITS 143
      • 8.2.5.11 ENTEROVIRUS KITS 143
      • 8.2.5.12 JCV KITS 143
      • 8.2.5.13 HHV6 KITS 143
      • 8.2.5.14 HHV7 KITS 143
      • 8.2.5.15 HHV8 KITS 143
      • 8.2.5.16 TOXOPLASMA GONDII KITS 143
      • 8.2.5.17 HEPATITIS E KITS 144
      • 8.2.5.18 OTHER KITS 144
    • 8.2.6 OTHER KITS 144
  • 8.3 TRANSPLANT DIAGNOSTIC SOFTWARE'S 144
    • 8.3.1 DNA SOFTWARE 145
    • 8.3.2 NGS SOFTWARE 145
    • 8.3.3 DATA MANAGEMENT SOFTWARE 145
    • 8.3.4 OTHER SOFTWARE'S 145
  • 8.4 TRANSPLANT DIAGNOSTIC REAGENTS 145
    • 8.4.1 MONOCLONAL ANTIBODIES 146
    • 8.4.2 CYTOTOXIC CONTROLS 146
    • 8.4.3 HUMAN SERUM 146
    • 8.4.4 OTHER REAGENTS 146

9 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY 147

  • 9.1 OVERVIEW 148
  • 9.2 PCR-BASED MOLECULAR ASSAYS 151
    • 9.2.1 REAL TIME PCR 151
    • 9.2.2 SEQUENCE-SPECIFIC PRIMER-PCR 151
    • 9.2.3 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR 152
    • 9.2.4 RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP) 152
    • 9.2.5 OTHER-PCR BASED MOLECULAR ASSAYS 152
  • 9.3 SEQUENCING-BASED MOLECULAR ASSAYS 152
    • 9.3.1 SANGER SEQUENCING 153
    • 9.3.2 NEXT GENERATION SEQUENCING 153
    • 9.3.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS. 153

10 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE 154

  • 10.1 OVERVIEW 155
  • 10.2 SOLID ORGAN TRANSPLANTATION 158
    • 10.2.1 KIDNEY TRANSPLANTATION 158
    • 10.2.2 LIVER TRANSPLANTATION 158
    • 10.2.3 HEART TRANSPLANTATION 159
    • 10.2.4 LUNG TRANSPLANTATION 159
    • 10.2.5 PANCREAS TRANSPLANTATION 159
    • 10.2.6 OTHER ORGAN TRANSPLANTATIONS 159
  • 10.3 STEM CELL TRANSPLANTATION 159
    • 10.3.1 BONE MARROW TRANSPLANT (BMT) 160
    • 10.3.2 PERIPHERAL BLOOD STEM CELL TRANSPLANT 160
    • 10.3.3 CORD BLOOD TRANSPLANT 160
    • 10.3.4 OTHER STEM CELL TRANSPLANTS 160
  • 10.4 SOFT TISSUE TRANSPLANTATION 160
    • 10.4.1 SKIN GRAFT 161
    • 10.4.2 CARTILAGE TRANSPLANTATION 161
    • 10.4.3 ADRENAL AUTOGRAFTING 161
    • 10.4.4 OTHER SOFT TISSUE TRANSPLANTATION. 161
  • 10.5 BONE MARROW TRANSPLANTATION 162
    • 10.5.1 AUTOLOGOUS BONE MARROW TRANSPLANT 162
    • 10.5.2 ALLOGENEIC BONE MARROW TRANSPLANT 162
    • 10.5.3 UMBILICAL CORD BLOOD TRANSPLANT. 163
  • 10.6 OTHERS 163

11 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 164

  • 11.1 OVERVIEW 165
  • 11.2 DIAGNOSTIC APPLICATIONS 168
    • 11.2.1 TRANSPLANT DIAGNOSTIC INSTRUMENT 168
      • 11.2.1.1 AUTOMATED PIPETTORS & DISPENSERS 169
      • 11.2.1.2 AUTOMATED SYSTEMS 169
      • 11.2.1.3 NGS INSTRUMENTS 169
      • 11.2.1.4 READERS & ANALYZERS 169
      • 11.2.1.5 TRANSPLANT DIAGNOSTIC KITS 169
      • 11.2.1.6 OTHERS 169
    • 11.2.2 TRANSPLANT DIAGNOSTIC SOFTWARE 169
      • 11.2.2.1 DNA SOFTWARE 170
      • 11.2.2.2 NGS SOFTWARE 170
      • 11.2.2.3 DATA MANAGEMENT SOFTWARE 170
      • 11.2.2.4 OTHER SOFTWARES 170
    • 11.2.3 TRANSPLANT DIAGNOSTIC REAGENT 170
      • 11.2.3.1 MONOCLONAL ANTIBODIES 171
      • 11.2.3.2 CYTOTOXIC CONTROLS 171
      • 11.2.3.3 HUMAN SERUM 171
      • 11.2.3.4 OTHER REAGENTS 171
  • 11.3 RESEARCH APPLICATIONS 171
    • 11.3.1 TRANSPLANT DIAGNOSTIC INSTRUMENT 172
      • 11.3.1.1 AUTOMATED PIPETTORS & DISPENSERS 173
      • 11.3.1.2 AUTOMATED SYSTEMS 173
      • 11.3.1.3 NGS INSTRUMENTS 173
      • 11.3.1.4 READERS & ANALYZERS 173
      • 11.3.1.5 TRANSPLANT DIAGNOSTIC KITS 173
      • 11.3.1.6 OTHERS 173
    • 11.3.2 TRANSPLANT DIAGNOSTIC SOFTWARE 173
      • 11.3.2.1 DNA SOFTWARE 174
      • 11.3.2.2 NGS SOFTWARE 174
      • 11.3.2.3 DATA MANAGEMENT SOFTWARE 174
      • 11.3.2.4 OTHER SOFTWARES 174
    • 11.3.3 TRANSPLANT DIAGNOSTIC REAGENT 174
      • 11.3.3.1 MONOCLONAL ANTIBODIES 175
      • 11.3.3.2 CYTOTOXIC CONTROLS 175
      • 11.3.3.3 HUMAN SERUM 175
      • 11.3.3.4 OTHER REAGENTS 175

12 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY END USER 176

  • 12.1 OVERVIEW 177
  • 12.2 HOSPITALS AND TRANSPLANT CENTERS 180
  • 12.3 COMMERCIAL SERVICE PROVIDERS 180
  • 12.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 180
  • 12.5 OTHERS 181

13 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 182

  • 13.1 OVERVIEW 183
  • 13.2 DIRECT TENDER 186
  • 13.3 RETAIL SALES 186
  • 13.4 OTHERS 186

14 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY REGION 188

  • 14.1 OVERVIEW 189
  • 14.2 NORTH AMERICA 194
    • 14.2.1 U.S. 206
    • 14.2.2 CANADA 218
    • 14.2.3 MEXICO 230
  • 14.3 ASIA-PACIFIC 242
    • 14.3.1 CHINA 256
    • 14.3.2 JAPAN 268
    • 14.3.3 SOUTH KOREA 280
    • 14.3.4 INDIA 292
    • 14.3.5 AUSTRALIA 304
    • 14.3.6 SINGAPORE 316
    • 14.3.7 THAILAND 328
    • 14.3.8 MALAYSIA 340
    • 14.3.9 INDONESIA 352
    • 14.3.10 PHILIPPINES 364
    • 14.3.11 REST OF ASIA-PACIFIC 376
  • 14.4 EUROPE 377
    • 14.4.1 GERMANY 392
    • 14.4.2 FRANCE 404
    • 14.4.3 U.K. 416
    • 14.4.4 ITALY 428
    • 14.4.5 RUSSIA 440
    • 14.4.6 SPAIN 452
    • 14.4.7 TURKEY 464
    • 14.4.8 NETHERLANDS 476
    • 14.4.9 SWITZERLAND 488
    • 14.4.10 BELGIUM 500
    • 14.4.11 REST OF EUROPE 512
  • 14.5 SOUTH AMERICA 513
    • 14.5.1 BRAZIL 525
    • 14.5.2 ARGENTINA 537
    • 14.5.3 REST OF SOUTH AMERICA 549
  • 14.6 MIDDLE EAST & AFRICA 550
    • 14.6.1 SOUTH AFRICA 563
    • 14.6.2 SAUDI ARABIA 575
    • 14.6.3 U.A.E 587
    • 14.6.4 EGYPT 599
    • 14.6.5 ISRAEL 611
    • 14.6.6 REST OF MIDDLE EAST AND AFRICA 623

15 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: COMPANY LANDSCAPE 624

  • 15.1 COMPANY SHARE ANALYSIS: GLOBAL 624
  • 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 625
  • 15.3 COMPANY SHARE ANALYSIS: EUROPE 626
  • 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 627

16 SWOT ANALYSIS 628

17 COMPANY PROFILE 629

  • 17.1 ABBOTT 629
    • 17.1.1 COMPANY SNAPSHOT 629
    • 17.1.2 REVENUE ANALYSIS 629
    • 17.1.3 COMPANY SHARE ANALYSIS 630
    • 17.1.4 PRODUCT PORTFOLIO 630
    • 17.1.5 RECENT DEVELOPMENTS 630
  • 17.2 THERMO FISHER SCIENTIFIC INC. 631
    • 17.2.1 COMPANY SNAPSHOT 631
    • 17.2.2 REVENUE ANALYSIS 631
    • 17.2.3 COMPANY SHARE ANALYSIS 632
    • 17.2.4 PRODUCT PORTFOLIO 632
    • 17.2.5 RECENT DEVELOPMENTS 634
  • 17.3 F. HOFFMANN LA ROCHE LTD 635
    • 17.3.1 COMPANY SNAPSHOT 635
    • 17.3.2 REVENUE ANALYSIS 635
    • 17.3.3 COMPANY SHARE ANALYSIS 636
    • 17.3.4 PRODUCT PORTFOLIO 636
    • 17.3.5 RECENT DEVELOPMENT 637
  • 17.4 TAKARA BIO INC. 638
    • 17.4.1 COMPANY SNAPSHOT 638
    • 17.4.2 REVENUE ANALYSIS 638
    • 17.4.3 COMPANY SHARE ANALYSIS 639
    • 17.4.4 PRODUCT PORTFOLIO 639
    • 17.4.5 RECENT DEVELOPMENTS 639
  • 17.5 HOLOGIC, INC 640
    • 17.5.1 COMPANY SNAPSHOT 640
    • 17.5.2 REVENUE ANALYSIS 640
    • 17.5.3 COMPANY SHARE ANALYSIS 641
    • 17.5.4 PRODUCT PORTFOLIO 641
    • 17.5.5 RECENT DEVELOPMENTS 642
  • 17.6 ADAPTIVE BIOTECHNOLOGIES 643
    • 17.6.1 COMPANY SNAPSHOT 643
    • 17.6.2 REVENUE ANALYSIS 643
    • 17.6.3 PRODUCT PORTFOLIO 644
    • 17.6.4 RECENT DEVELOPMENT 644
  • 17.7 ALTONA DIAGNOSTICS 645
    • 17.7.1 COMPANY SNAPSHOT 645
    • 17.7.2 PRODUCT PORTFOLIO 645
    • 17.7.3 RECENT DEVELOPMENTS 645
  • 17.8 ARQUER DIAGNOSTICS LTD 646
    • 17.8.1 COMPANY SNAPSHOT 646
    • 17.8.2 PRODUCT PORTFOLIO 646
    • 17.8.3 RECENT DEVELOPMENTS 647
  • 17.9 BAG DIAGNOSTICS GMBH 648
    • 17.9.1 COMPANY SNAPSHOT 648
    • 17.9.2 PRODUCT PORTFOLIO 648
    • 17.9.3 RECENT DEVELOPMENTS 648
  • 17.10 BIOFORTUNA LIMITED 649
    • 17.10.1 COMPANY SNAPSHOT 649
    • 17.10.2 PRODUCT PORTFOLIO 649
    • 17.10.3 RECENT DEVELOPMENT 649
  • 17.11 BIOMERIEUX 650
    • 17.11.1 COMPANY SNAPSHOT 650
    • 17.11.2 REVENUE ANALYSIS 650
    • 17.11.3 PRODUCT PORTFOLIO 651
    • 17.11.4 RECENT DEVELOPMENTS 651
  • 17.12 BIO-RAD LABORATORIES, INC. 652
    • 17.12.1 COMPANY SNAPSHOT 652
    • 17.12.2 REVENUE ANALYSIS 652
    • 17.12.3 PRODUCT PORTFOLIO 653
    • 17.12.4 RECENT DEVELOPMENT 654
  • 17.13 BIOTYPE GMBH 655
    • 17.13.1 COMPANY SNAPSHOT 655
    • 17.13.2 PRODUCT PORTFOLIO 655
    • 17.13.3 RECENT DEVELOPMENTS 656
  • 17.14 CAREDX INC. 657
    • 17.14.1 COMPANY SNAPSHOT 657
    • 17.14.2 REVENUE ANALYSIS 657
    • 17.14.3 PRODUCT PORTFOLIO 658
    • 17.14.4 RECENT DEVELOPMENTS 660
  • 17.15 CLONIT SRL 661
    • 17.15.1 COMPANY SNAPSHOT 661
    • 17.15.2 PRODUCT PORTFOLIO 661
    • 17.15.3 RECENT DEVELOPMENT 663
  • 17.16 DIAGNOSTICA LONGWOOD SL 664
    • 17.16.1 COMPANY SNAPSHOT 664
    • 17.16.2 PRODUCT PORTFOLIO 664
    • 17.16.3 RECENT DEVELOPMENTS 664
  • 17.17 DIASORIN S.P.A. 665
    • 17.17.1 COMPANY SNAPSHOT 665
    • 17.17.2 REVENUE ANALYSIS 665
    • 17.17.3 PRODUCT PORTFOLIO 666
    • 17.17.4 RECENT DEVELOPMENT 666
  • 17.18 ELITECHGROUP 667
    • 17.18.1 COMPANY SNAPSHOT 667
    • 17.18.2 PRODUCT PORTFOLIO 667
    • 17.18.3 RECENT DEVELOPMENTS 667
  • 17.19 EUROFINS VIRACOR 668
    • 17.19.1 COMPANY SNAPSHOT 668
    • 17.19.2 PRODUCT PORTFOLIO 668
    • 17.19.3 RECENT DEVELOPMENTS 669
  • 17.20 HORIBA LTD 670
    • 17.20.1 COMPANY SNAPSHOT 670
    • 17.20.2 REVENUE ANALYSIS 670
    • 17.20.3 PRODUCT PORTFOLIO 671
    • 17.20.4 RECENT DEVELOPMENT 671
  • 17.21 ILLUMINA, INC. 672
    • 17.21.1 COMPANY SNAPSHOT 672
    • 17.21.2 REVENUE ANALYSIS 672
    • 17.21.3 PRODUCT PORTFOLIO 673
    • 17.21.4 RECENT DEVELOPMENTS 673
  • 17.22 IMMUCOR 674
    • 17.22.1 COMPANY SNAPSHOT 674
    • 17.22.2 PRODUCT PORTFOLIO 674
    • 17.22.3 RECENT DEVELOPMENTS 674
  • 17.23 LABORATORY CORPORATION OF AMERICA HOLDINGS. 675
    • 17.23.1 COMPANY SNAPSHOT 675
    • 17.23.2 REVENUE ANALYSIS 675
    • 17.23.3 PRODUCT PORTFOLIO 676
    • 17.23.4 RECENT DEVELOPMENTS 677
  • 17.24 LUMINEX CORPORATION. (A SUBSIDIARY OF DIASORIN) 678
    • 17.24.1 COMPANY SNAPSHOT 678
    • 17.24.2 REVENUE ANALYSIS 678
    • 17.24.3 PRODUCT PORTFOLIO 679
    • 17.24.4 RECENT DEVELOPMENT 679
  • 17.25 NANOSTRING 680
    • 17.25.1 COMPANY SNAPSHOT 680
    • 17.25.2 REVENUE ANALYSIS 680
    • 17.25.3 PRODUCT PORTFOLIO 681
    • 17.25.4 RECENT DEVELOPMENT 681
  • 17.26 PATHONOSTICS 682
    • 17.26.1 COMPANY SNAPSHOT 682
    • 17.26.2 PRODUCT PORTFOLIO 682
    • 17.26.3 RECENT DEVELOPMENTS 682
  • 17.27 PRESERVATION SOLUTIONS, INC. 683
    • 17.27.1 COMPANY SNAPSHOT 683
    • 17.27.2 PRODUCT PORTFOLIO 683
    • 17.27.3 RECENT DEVELOPMENTS 683
  • 17.28 QIAGEN 684
    • 17.28.1 COMPANY SNAPSHOT 684
    • 17.28.2 REVENUE ANALYSIS 684
    • 17.28.3 PRODUCT PORTFOLIO 685
    • 17.28.4 RECENT DEVELOPMENTS 686
  • 17.29 RANDOX LABORATORIES LTD. 687
    • 17.29.1 COMPANY SNAPSHOT 687
    • 17.29.2 PRODUCT PORTFOLIO 687
    • 17.29.3 RECENT DEVELOPMENTS 688
  • 17.30 STRYKER 689
    • 17.30.1 COMPANY SNAPSHOT 689
    • 17.30.2 REVENUE ANALYSIS 689
    • 17.30.3 PRODUCT PORTFOLIO 690
    • 17.30.4 RECENT DEVELOPMENT 690
  • 17.31 TRANSMEDICS 691
    • 17.31.1 COMPANY SNAPSHOT 691
    • 17.31.2 REVENUE ANALYSIS 691
    • 17.31.3 PRODUCT PORTFOLIO 692
    • 17.31.4 RECENT DEVELOPMENTS 692
  • 17.32 TRANSONIC. 693
    • 17.32.1 COMPANY SNAPSHOT 693
    • 17.32.2 PRODUCT PORTFOLIO 693
    • 17.32.3 RECENT DEVELOPMENT 693
  • 17.33 ZIMMER BIOMET 694
    • 17.33.1 COMPANY SNAPSHOT 694
    • 17.33.2 REVENUE ANALYSIS 694
    • 17.33.3 PRODUCT PORTFOLIO 695
    • 17.33.4 RECENT DEVELOPMENTS 695

18 QUESTIONNAIRE 696

19 RELATED REPORTS 699

LIST OF FIGURES

  • FIGURE 1 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: SEGMENTATION 84
  • FIGURE 2 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: DATA TRIANGULATION 87
  • FIGURE 3 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: DROC ANALYSIS 88
  • FIGURE 4 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 89
  • FIGURE 5 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 89
  • FIGURE 6 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 90
  • FIGURE 7 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 92
  • FIGURE 8 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 94
  • FIGURE 9 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 95
  • FIGURE 10 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: SEGMENTATION 99
  • FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET, AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 100
  • FIGURE 12 INCREASING USE OF TRANSPLANT DIAGNOSTICS IS EXPECTED TO DRIVE THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET IN THE FORECAST PERIOD 101
  • FIGURE 13 TRANSPLANT DIAGNOSTIC INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET IN 2022 & 2029 101
  • FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR TRANSPLANT DIAGNOSTICS MANUFACTURERS IN THE FORECAST PERIOD 102
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET 129
  • FIGURE 16 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2021 137
  • FIGURE 17 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION) 138
  • FIGURE 18 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2022-2029) 138
  • FIGURE 19 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 139
  • FIGURE 20 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, 2021 148
  • FIGURE 21 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022-2029 (USD MILLION) 149
  • FIGURE 22 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2022-2029) 149
  • FIGURE 23 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE 150
  • FIGURE 24 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, 2021 155
  • FIGURE 25 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, 2022-2029 (USD MILLION) 156
  • FIGURE 26 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, CAGR (2022-2029) 156
  • FIGURE 27 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY TRANSPLANT TYPE, LIFELINE CURVE 157
  • FIGURE 28 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, 2021 165
  • FIGURE 29 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, 2022-2029 (USD MILLION) 166
  • FIGURE 30 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2022-2029) 166
  • FIGURE 31 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE 167
  • FIGURE 32 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY END USER, 2021 177
  • FIGURE 33 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY END USER, 2022-2029 (USD MILLION) 178
  • FIGURE 34 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY END USER, CAGR (2022-2029) 178
  • FIGURE 35 GLOBAL TRANSPLANT DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 179
  • FIGURE 36 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2021 183
  • FIGURE 37 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 184
  • FIGURE 38 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 184
  • FIGURE 39 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 185
  • FIGURE 40 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021) 190
  • FIGURE 41 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY REGION (2021) 191
  • FIGURE 42 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY REGION (2022 & 2029) 191
  • FIGURE 43 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY REGION (2021 & 2029) 192
  • FIGURE 44 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029) 192
  • FIGURE 45 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021) 195
  • FIGURE 46 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021) 196
  • FIGURE 47 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029) 196
  • FIGURE 48 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029) 197
  • FIGURE 49 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029) 197
  • FIGURE 50 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021) 243
  • FIGURE 51 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021) 244
  • FIGURE 52 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029) 244
  • FIGURE 53 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029) 245
  • FIGURE 54 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029) 245
  • FIGURE 55 EUROPE TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021) 378
  • FIGURE 56 EUROPE TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021) 379
  • FIGURE 57 EUROPE TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029) 379
  • FIGURE 58 EUROPE TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029) 380
  • FIGURE 59 EUROPE TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029) 381
  • FIGURE 60 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021) 514
  • FIGURE 61 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021) 515
  • FIGURE 62 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029) 515
  • FIGURE 63 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029) 516
  • FIGURE 64 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029) 516
  • FIGURE 65 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET: SNAPSHOT (2021) 551
  • FIGURE 66 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021) 552
  • FIGURE 67 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029) 552
  • FIGURE 68 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029) 553
  • FIGURE 69 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET: BY PRODUCT TYPE (2022-2029) 553
  • FIGURE 70 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%) 624
  • FIGURE 71 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%) 625
  • FIGURE 72 EUROPE TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%) 626
  • FIGURE 73 ASIA-PACIFIC TRANSPLANT DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%) 627